Special article

Recommendations to improve lipid control in primary prevention patients. A consensus document of the Spanish Society of Cardiology

Vivencio Barrios¹,*, Carlos Escobar⁵, Manuel Anguita⁵, Vicente Ignacio Arrarte Esteban⁴, Raquel Campuzano Ruiz⁴, Juan Cosín-Sales⁴, M. Isabel Egocheaga Cabello⁹, José María Gámez⁶, Carlos Guirarro⁵, José M. Mostaza⁷, Juan Carlos Obaya Rebollar⁸, Vicente Pallarés-Carratalá⁹, María Seoane Vicente¹⁰, Pedro Valdivielso¹¹, Ángel Cequier¹²

¹ Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, Spain
² Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain
³ Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain
⁴ Servicio de Cardiología, Hospital General Universitario de Alicante, Alicante, Spain
⁵ Unidad de Rehabilitación Cardiaca, Servicio de Cardiología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain
⁶ Servicio de Cardiología, Hospital Arnau de Vilanova, Valencia, Spain
⁷ Centro de Salud Isla de Oza, Madrid, Spain
⁸ Servicio de Cardiología, Hospital Universitario Son Llàtzer, Palma de Mallorca, Baleares, Spain
⁹ Unidad de Medicina Interna, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain
¹⁰ Servicio de Medicina Interna, Hospital Carlos III, Madrid, Spain
¹¹ Centro de Salud La Chopera, Alcobendas, Madrid, Spain
¹² Unidad de Vigilancia de la Salud, Unión de Mutuas, Castellón, Spain
¹³ Centro de Salud Aequión, Torrevieja, Alicante, Spain
¹⁴ Servicio de Medicina Interna, Hospital Virgen de la Victoria, Málaga, Spain
¹⁵ Servicio de Cardiología, Hospital Universitario de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain

A R T I C L E  I N F O

Article history:
Received 26 January 2021
Accepted 17 February 2021
Available online 10 June 2021

Keywords:
LDL cholesterol
Primary prevention
Lipid lowering therapy

A B S T R A C T

The reduction of low-density lipoprotein cholesterol with lipid lowering therapy has demonstrated to decrease the risk of developing cardiovascular complications during the follow-up in primary and secondary prevention. Unfortunately, a great number of patients do not achieve recommended targets. This is mainly due to an insufficient use of the lipid-lowering therapy currently available. Although healthy life style changes are the basis of the treatment, in many cases this is not enough and it is necessary to add lipid lowering drugs to attain these targets. For these reasons, the current consensus document of the Spanish
La reducción del colesterol unido a lipoproteínas de baja densidad con el tratamiento hipolipemante ha demostrado disminuir el riesgo de complicaciones cardiovasculares durante el seguimiento, tanto en prevención primaria como secundaria. Desafortunadamente, un gran número de pacientes no logran los objetivos de control recomendados. Esto se debe, sobre todo, a un uso insuficiente de las terapias hipolipemiantes disponibles. Aunque la base del tratamiento lo constituyen los cambios hacia un estilo de vida más saludable, en numerosas ocasiones esto no es suficiente y es necesario añadir un tratamiento hipolipemante para alcanzar estos objetivos. Por estos motivos, en el presente documento de consenso de la Sociedad Española de Cardiología se proponen 4 algoritmos de abordaje en función del riesgo cardiovascular de los pacientes, sencillos y fácilmente aplicables, con el objetivo de lograr que la mayoría de los pacientes en prevención primaria cumplan los objetivos de control de colesterol de manera rápida y eficiente.

© 2021 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY (http://creativecommons.org/licenses/by/4.0/).
as well. The 2019 European guidelines for dyslipidemia propose a stepwise treatment strategy, which could delay the achievement of LDLc objectives, especially in patients with the highest CV risk. Recently, the American Association of Clinical Endocrinologists and the American College of Endocrinology have proposed several algorithms for the treatment of dyslipidemia, depending on CV risk.26 However, these associations use a scale for stratifying CV risk that differs from the European scale, and consequently its application is difficult in our environment. Therefore, there is a need to create specific algorithms in primary prevention to improve the approach to these patients in our milieu both rapidly and effectively. The present consensus document of the SEC describes several algorithms for the optimization of lipid-lowering therapy in primary prevention, depending on CV risk. The document is the result of the participation of experts in dyslipidemia from distinct specialties (cardiology, internal medicine, and primary care).

### Cardiovascular risk stratification

The guidelines of the European Society of Cardiology and the European Society of Atherosclerosis for the treatment of patients with dyslipidemia recommend CV risk stratification through the Systematic Coronary Risk Estimation (SCORE) chart which, in the case of Spain, corresponds to low-risk European regions.4

Considering the information available from various studies, in the present consensus document, we decided to add certain patient profiles to the CV risk chart proposed by the European guidelines on dyslipidemia. In chronic kidney disease, CV risk is increased not only by a reduced glomerular filtration rate but also by the presence of albuminuria.27 Consequently, we believe that patients with a glomerular filtration rate of 30–59 mL/min/1.73 m² and albuminuria ≥ 30 mg/g have very high CV risk. In addition, in patients with hypertension, the presence of associated organ damage (left ventricular hypertrophy and oligoalbuminuria) confers an elevated CV risk.28 High lipoprotein(a)—Lp(a)—levels are associated with an increased risk of CV events. In agreement with the European guidelines on dyslipidemia, persons with Lp(a) levels >180 mg/dL have a similar risk of developing atherosclerotic CV disease to patients with heterozygous familial hypercholesterolemia, and consequently persons with Lp(a) levels >180 mg/dL associated with at least 1 CV risk factor should be considered as being at elevated CV risk.5 In agreement with the SCORE charts for low-risk countries, non-smoking men, with blood pressure 120 mmHg and total cholesterol 155 mg/dL, in the absence of other risk factors and without CV disease, would have a SCORE risk of 1% at the age of 55 years. In women, this profile corresponds to those aged 60

| **Table 1 – Cardiovascular risk stratification in patients in primary prevention.** |
|------------------------------------------|------------------------------------------|
| **Very high risk**                       | **Factors modifying risk:**               |
| Type 2 diabetes with microvascular lesion or >3 | Lipoprotein(a): between 50 and 180 mg/dL |
| CVRF or type 1 diabetes with onset >20 y previously | CT-detected coronary calcification (score > 100, moderate disease; score > 400, severe disease) |
| GFR < 30 mL/min/1.73 m² or GFR 30–59 mL/min/1.73 m² with albuminuria ≥ 30 mg/g | Central obesity |
| Familial hypercholesterolemia with another CVRF | Family history of premature CVD (male < 55 y, female < 60 y) |
| Significant subclinical vascular disease in both coronary and carotid regions | Sedentariness |
| **SCORE ≥ 10%**                           | **Chronic inflammatory diseases**         |
| **High risk**                             |                                           |
| Very high isolated CVRF (SBP ≥ 180/110 mmHg; total cholesterol > 310 mg/dL; LDLc > 190 mg/dL) | HIV treatment |
| Diabetes without microvascular lesions but with at least 1 CVRF or onset 10–20 y previously | Attrial fibrillation |
| Moderate chronic kidney disease (GFR 30–59 mL/min/1.73 m² without albuminuria) | Non-alcoholic fatty liver disease |
| HT with TOD                               | OSAS                                      |
| Familial hypercholesterolemia without another CVRF | CTx/RTx                                  |
| Lipoprotein(a) ≥ 180 mg/dL and at least 1 CVRF | Major psychiatric disorders               |
| **SCORE ≥ 5–10%**                         | Low socioeconomic status                  |
| **Moderate risk**                         | Pre-eclampsia, premature delivery        |
| Male > 55 y or female > 60 y without other CVRF | Early menopause                         |
| Diabetes in young persons (type 1 < 35 y; type 2 < 50 y) with <10 y since onset, without other CVRF or microvascular lesions | Gestational diabetes                     |
| **SCORE ≥ 1–<5%**                         | Persistent triglyceride levels ≥ 175 mg/dL |
| **Low risk**                              | Ankle-ankle index                        |
| **SCORE < 1%**                            |                                           |

CTx, chemotherapy; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; GFR, glomerular filtration rate; HIV, human immunodeficiency virus; HT, hypertension; LDLc, low-density lipoprotein cholesterol; OSAS, obstructive sleep apnea syndrome; SBP, systolic blood pressure; TOD, target organ damage; RTx, radiotherapy.

Table based on Mach et al.,4 Pencina et al.,24 López-Fernández et al.,25 and Arnett et al.30
years.\(^4\) For this reason, it has been specified that men >55 years and women >60 years without other risk factors for CV disease should be considered as being at moderate risk. Table 1 specifies the factors that should be considered as increasing risk.\(^4,24,29,30\)

In agreement with the European guidelines on dyslipidemia, we propose goals of LDLc < 55 mg/dL and a reduction of at least 50% in persons at very high CV risk, LDLc < 70 mg/dL and a reduction of at least 50% in individuals at high CV risk, LDLc < 100 mg/dL in persons at moderate CV risk, and LDLc < 116 mg/dL in those at low CV risk.\(^4\)

### LDLc-lowering treatments

All patients with dyslipidemia should be encouraged to make lifestyle changes, including following the Mediterranean diet, abstaining from smoking, taking physical exercise, and losing weight if they are overweight or obese, in addition to controlling the remaining CV risk factors.\(^4\)

Dietary recommendations advise a healthy diet, with low saturated fat intake and rich in wholemeal products, fruit, vegetables, and fish. The Mediterranean diet is recommended, among others. The PREDIMED trial demonstrated that the Mediterranean diet supplemented with extra virgin olive oil and dried fruits can significantly reduce (almost by 30%) the rate of major CV events compared with a low-fat diet.\(^32\) However, the main problem of this enriched diet is follow-up and long-term adherence.\(^32\) Therefore, its ability to reduce LDLc depends on individuals’ persistence in following it.

In addition to making lifestyle changes, patients at high or very high CV risk should be started on lipid-lowering therapy to achieve LDLc goals. In contrast, patients with low or moderate CV risk should begin with lifestyle changes and, if these prove insufficient, lipid-lowering therapy should be considered. In these patients, the delay in starting lipid-lowering therapy depends on their adherence to diet and physical exercise, their baseline LDLc value (the higher the LDLc level, the shorter the delay), the patient’s CV risk, and whether there are other factors that could increase CV risk.\(^3\) For example, in patients with low CV risk, who are usually young, the need for lipid-lowering therapy should be discussed, stressing the advi-

---

**Fig. 1 – Algorithm for the approach to lipid-lowering treatment in patients with very high CV risk. Recommendations of the Spanish Society of Atherosclerosis (SEA): use of PCSK9 inhibitors in primary prevention: homozygous familial hypercholesterolemia and LDLc > 100 mg/dL; heterozygous familial hypercholesterolemia with >4 associated risk factors and LDLc > 130 mg/dL or diabetes and LDLc > 100 mg/dL; CKD ≥ 3b (no dialysis) with diabetes and LDLc > 130 mg/dL.\(^45\)**

According to the 2019 European guidelines on dyslipidemia,\(^4\) in patients in primary prevention with very high risk and no familial hypercholesterolemia, the addition of a PCSK9 inhibitor can be considered when the LDLc target is not achieved with the combination of maximum tolerated dose and ezetimibe. In patients with familial hypercholesterolemia and very high risk who do not achieve the LDLc goal with the combination of maximum tolerated statin dose and ezetimibe, addition of a PCSK9 inhibitor is recommended. CKD, chronic kidney disease; CV, cardiovascular; LDLc, low-density lipoprotein cholesterol.

Figure adapted with permission from Escobar et al.\(^21\)
sability of achieving a healthy lifestyle, especially in patients whose cholesterol levels are not very high, since these measures can be sufficient in a substantial number of individuals.

With regard to food supplements, the European guidelines on dyslipidemia state that the available evidence on the effect of nutraceuticals on lipid profile is incomplete. An important nutraceutical, among others, is red yeast rice (monacolin K), which has been demonstrated to be effective in reducing LDLc. Nevertheless, the safest dose is monacolin K 3 mg since the highest dose (10 mg) has the same adverse effects as statins. Nutraceuticals combining several natural components are those with the highest efficacy. Among the various nutraceuticals, those supported by the most robust scientific evidence should be used. Their main indication is in patients with low CV risk, in whom lifestyle modification is insufficient to achieve LDLc goals and the option of statin use is not preferred (patient preference, adverse effects of statins, etc.).

Statins reduce cholesterol synthesis by the liver through competitive inhibition of 3-hydroxy-3-methyl-glutaryl-CoA reductase. Although all statins share the same mechanism, not all reduce LDLc with the same intensity. High-intensity statins reduce LDLc by about 50% from baseline levels, moderate-intensity statins lower LDLc by 30% to 50%, and low intensity statins decrease LDLc by less than 30%. Nevertheless, there is wide interindividual variability in response to statin therapy. In addition, the risk of adverse effects, mainly hepatic (transaminase elevation) and muscular (myalgia, creatine-phosphokinase elevation), also differs among statins. Statins with the least risk of interactions are those with the lowest possibility of producing adverse effects. Thus, statins not metabolized by cytochrome P450 (pravastatin, rosuvastatin, and pitavastatin) have a lower risk of interactions. In primary prevention, statins have been demonstrated to improve CV prognosis. For example, in the JUPITER trial, which included approximately 18,000 patients without prior CV disease, with a LDLc ≤ 130 mg/dL and high-sensitivity C-reactive protein ≥ 2.0 mg/L, treatment with rosuvastatin 20 mg/d compared with placebo was associated with a significant reduction in the risk of major CV events of 47%, and the risk of all-cause mortality was reduced by 20% with only 1.9 years of follow-up. Therefore, statins are the treatment of choice in primary prevention in persons not achieving LDLc goals after making lifestyle changes. The statin chosen should be that producing the required LDLc reduction, with the best safety profile.

Ezetimibe inhibits the absorption of biliary and dietary cholesterol from the intestine but without affecting the

**Table 1: Intensity of LDLc Reduction**

<table>
<thead>
<tr>
<th>Intensity of LDLc reduction</th>
<th>LDLc reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extreme (&gt; 75%)</td>
<td>High (50%–75%)</td>
</tr>
<tr>
<td>Very high (60%–75%)</td>
<td>Moderate (30%–49%)</td>
</tr>
</tbody>
</table>

* Population requiring evaluation of the introduction of PCSK9 inhibitors, if simple association with ezetimibe does not achieve goals (individualize according to LDLc value and the patient’s characteristics.

** Consider moderate-intensity statins in patients who are elderly, frail, or who have contraindications for the use of high-intensity statins and, if a reduction < 50% is needed, consider adding ezetimibe or titrating statins.

*** If an LDLc reduction ≥ 50% has not been achieved.

Fig. 2 – Algorithm for the approach to lipid-lowering treatment in patients with high cardiovascular risk. Recommendations of the Spanish Society of Atherosclerosis (SEA): use of PCSK9 inhibitors in primary prevention: homozygous familial hypercholesterolemia and LDLc > 100 mg/dL; heterozygous familial hypercholesterolemia with ≥ 4 associated risk factors and LDLc > 130 mg/dL or diabetes and LDLc > 100 mg/dL; CKD ≥ 3b (no dialysis) with diabetes and LDLc > 130 mg/dL. The 2019 European guidelines on dyslipidemia do not recommend the use of PCSK9 inhibitors in patients at high cardiovascular risk in primary prevention. CKD, chronic kidney disease; CV, cardiovascular; LDLc, low-density lipoprotein cholesterol. Figure adapted with permission from Escobar et al.
Healthy lifestyle changes should be encouraged in all patients (Mediterranean diet, abstinence from smoking, physical activity, control of other cardiovascular risk factors).

<table>
<thead>
<tr>
<th>Intensity of LDLc reduction</th>
<th>Therapeutic alternatives</th>
</tr>
</thead>
</table>
| LDLc reduction 76%-85%     | Maximal background lipid-lowering therapy + PCSK9 inhibitors*:  
|                           | • Evolocumab 140 mg (~85%)  
|                           | • Alirocumab 150 mg (~85%)  
|                           | • Alirocumab 75 mg (~76%)  |
| LDLc reduction 60%-75%     | High-intensity statin + ezetimibe 10 mg:  
|                           | • Atorvastatin 40-80 mg + ezetimibe 10 mg  
|                           | • Rosuvastatin 10-40 mg + ezetimibe 10 mg  |
| LDLc reduction 50-59%      | High-intensity statin:  
|                           | • Atorvastatin 40-80 mg  
|                           | • Rosuvastatin 20-40 mg  
|                           | Medium-intensity statin + ezetimibe:  
|                           | • Simvastatin 20-40 mg + ezetimibe 10 mg  
|                           | • Pravastatin 40 mg + ezetimibe 10 mg  
|                           | • Lovastatin 40 mg + ezetimibe 10 mg  
|                           | • Fluvastatin 80 mg + ezetimibe 10 mg  
|                           | • Pitavastatin 2-4 mg + ezetimibe 10 mg  
|                           | • Atorvastatin 10-20 mg + ezetimibe 10 mg  
|                           | • Rosuvastatin 5 mg + ezetimibe 10 mg |
| LDLc reduction 30%-49%     | Medium-intensity statin:  
|                           | • Atorvastatin 10-20 mg  
|                           | • Rosuvastatin 5-10 mg  
|                           | • Simvastatin 20-40 mg  
|                           | • Pravastatin 40 mg  
|                           | • Lovastatin 40 mg  
|                           | • Pitavastatin 2-4 mg  
|                           | • Fluvastatin XL 80 mg  
|                           | Low-intensity statin + ezetimibe:  
|                           | • Simvastatin 10 mg + ezetimibe 10 mg  
|                           | • Pravastatin 20 mg + ezetimibe 10 mg  
|                           | • Lovastatin 20 mg + ezetimibe 10 mg  
|                           | • Fluvastatin 40 mg + ezetimibe 10 mg  
|                           | • Pitavastatin 1 mg + ezetimibe 10 mg  
|                           | Benepoacid 180 mg + ezetimibe 10 mg |
| LDLc reduction < 30%       | Low-intensity statin:  
|                           | • Simvastatin 10 mg  
|                           | • Pravastatin 20 mg  
|                           | • Lovastatin 20 mg  
|                           | • Fluvastatin 40 mg  
|                           | • Pitavastatin 1 mg  
|                           | Ezetimibe 10 mg  
|                           | Combination of nutraceuticals with demonstrated efficacy in clinical trials  
|                           | Benepoacid 180 mg |

Fig. 3 – Classification of lipid-lowering therapy according to intensity of LDLc reduction. CVRF, cardiovascular risk factors; LDLc, low-density lipoprotein cholesterol. Figure adapted with permission from Escobar et al.\textsuperscript{21} and based on Mach et al.,\textsuperscript{4} Masana et al.,\textsuperscript{35} and Saeed et al.\textsuperscript{40} * In general, starting with maximal doses of PCSK9 inhibitors is recommended to achieve the maximum reduction possible from the outset.
In monotherapy, ezetimibe 10 mg/d reduces LDLc by around 15% to 22%, with substantial interindividual variability. When added to statin therapy, ezetimibe produces an additional decrease in LDLc of around 15%. However, to reduce LDLc, it is more effective to add ezetimibe to statin therapy than to double the statin dose. In the IMPROVE-IT trial, conducted in patients admitted for an ACS, the combination of simvastatin 40 mg with ezetimibe 10 mg (with a median LDLc level during follow-up of 55 mg/dL) was associated with a significant decrease in the composite endpoint of CV events vs simvastatin 40 mg monotherapy (median LDLc level of 70 mg/dL during follow-up), with no increase in the risk of adverse events.

Bempedoic acid inhibits cholesterol synthesis by inhibiting adenosine triphosphate citrate lyase, a cytosolic enzyme that acts before 3-hydroxy-3-methyl-glutaryl coenzyme reductase in the cholesterol biosynthetic pathway. Compared with placebo, bempedoic acid is able to reduce LDLc by between 27.4% and 28.5%, with additional decreases when used in combination with ezetimibe. Although currently ongoing studies will determine its ability to reduce CV events, a combined analysis of the available evidence showed that treatment with bempedoic acid could reduce the risk of major CV events (hazard ratio, 0.83; 95% confidence interval, 0.57–1.21). Bempedoic acid is indicated in combination with a statin or with a statin and other lipid-lowering treatments in patients not achieving target LDLc levels, or alone or in combination with other lipid-lowering treatments in statin-intolerant patients.

Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) markedly reduce LDLc. In the evolocumab arm of the FOURIER trial, which included patients with atherosclerotic CV disease, the mean LDLc value was 30 mg/dL, while in the alirocumab arm of the ODYSSEY OUTCOMES trial, which included patients with an ACS in the past 12 months, the initial reduction in LDLc was 38 mg/dL. In both trials, the addition of PCSK9i to the background lipid-lowering therapy was associated with a significant 15% reduction in the primary endpoint.

The European guidelines on dyslipidemia recommend the addition of PCSK9i inhibitors to treatment if LDLc goals are not achieved with statins at the maximum tolerated dose and ezetimibe in secondary prevention (class 1 recommendation, level of evidence A), familial hypercholesterolemia and very high CV risk (class 1 recommendation, level of evidence C). PCSK9i can also be considered in primary prevention in individuals with very high CV risk without familial hypercholesterolemia (class IIb recommendation, level of evidence C).

Recently, the Spanish Society of Atherosclerosis has published recommendations on the use of PCSK9i aimed

---

**Fig. 4 – Algorithm for the approach to lipid-lowering therapy in patients at moderate cardiovascular risk.**

**CV**, cardiovascular; **LDLc**, low-density lipoprotein cholesterol.
at patients who could obtain greater benefit from these drugs (Fig. 1 and Fig. 2).45

Fig. 3 summarizes the various lipid-lowering therapies, classified according to their ability to reduce LDLc in monotherapy or in combination.

Currently, new therapeutic options are under study that, in the future, will expand the number of currently available lipid-lowering treatments. Thus, inclisiran, a small chemically synthesized interfering RNA molecule administered every 6 months, reduces PCSK9 synthesis in the liver, reducing LCLc by around 50% to 55%.46 Drugs specifically designed to reduce Lp(a) are also under development. The most promising is pelacarsen, which is targeted to LPA mRNA and is administered every 2 to 4 weeks subcutaneously.47

Algorithm interpretation

This document presents 4 scenarios with a different approach according to patients’ CV risk. Lifestyle modifications are recommended in all scenarios and in patients with high or very high CV risk, in addition to initial drug therapy.

In patients with very high CV risk (Fig. 1), the target LDLc level is <55 mg/dL and a reduction of at least 50% in LDLc. As shown in Fig. 1, the treatment strategy depends on whether the patient is receiving statin therapy and whether these are prescribed at the maximum tolerated dose. Subsequently, depending on LDLc levels, treatment recommendations are made when attending the patient, according to the color code in Fig. 3, depending on the reduction needed in LDLc. Patients are reassessed in 4 to 6 weeks and lipid-lowering therapy is intensified, if necessary. This algorithm is similar to that proposed in the consensus document on secondary prevention of the SEC.19 In the case of patients in primary prevention, the evidence on the benefit of PCSK9i is less solid, especially in those without familial hypercholesterolemia.45 Interpretation of the algorithm is similar for patients with high CV risk (Fig. 2): an LDLc target of <70 mg/dL and an LDLc reduction of at least 50%. In patients with high CV risk, the recommendations for PCSK9i should be more restrictive.

In patients with moderate (Fig. 4) or low (Fig. 5) CV risk, it is important to stress the need for healthy lifestyle habits and to start lipid-lowering treatment if these are insufficient and LDLc levels are above recommended goals. The interval before starting lipid-lowering therapy will depend on the patient’s adherence to treatment, CV risk, and LDLc levels. Subsequently, and following the colors in Fig. 3, various treatment options can be chosen, depending on the patient’s CV risk and LDLc level. In both cases, the patient should be reassessed at 8 to 12 weeks.
Conclusions

Despite the demonstrated benefits of LDLc reduction in primary prevention, a large number of patients will not achieve target goals, representing an increase in the risk of CV complications. Although lifestyle changes form the basis of treatment, they are often insufficient and lipid-lowering therapy will be needed to achieve target levels. The 4 treatment algorithms presented in this document are simple to apply and aim to aid the therapeutic approach to patients with dyslipidemia in primary prevention.

Funding

This work was supported by an unconditional grant from Mylan and Almirall, which did not influence the content of the manuscript in any way.

Authors’ contributions

All authors contributed substantially to the conception, design, drafting, and review of the manuscript. Va. Barrios and C. Escobar also coordinated the study.

Conflicts of interest

V. Barrios and J. Cosín-Sales have received grants, speaker, and consultant fees from Sanofi, Almirall, MSD and Mylan. C. Escobar has received grants, speaker and consultant fees from Amgen, Sanofi, MSD, Mylan, Servier, Ferrer, Daiichi-Sankyo, and Novartis. V. Arrarte and M. Seoane have received grants, speaker and consultant fees from MSD, Amgen, Sanofi, Rovi, and Almirall. R. Campuzano has received grants, speaker and consultant fees from Amgen, Sanofi, MSD, Mylan, Servier, Ferrer, Daiichi-Sankyo, and Novartis. J.M. Gámez has received grants, speaker and consultant fees from Amgen, Sanofi, Mylan, Ferrer, Daiichi-Sankyo, and Novartis. C. Guijarro has received grants, speaker and consultant fees from Amgen, Sanofi, Daiichi Sankyo, Ferrer, Pfizer, Laboratorios Rubió and MSD. J.M. Mostaza has received grants, speaker or consultant fees from Amgen, Sanofi, Novartis, and Daiichi-Sankyo. P. Valdivielso has received grant, speaker and consultant fees from Ferrer, Amgen, Sanofi, Novartis, Daiichi-Sankyo, MSD, and Amarin. A. Cequier has received grants, speaker, and consultant fees from Abbott Vascular, Biosensors, Boston Scientific, Medtronic, Biomenc, Cordis, Orbus Neich, the Spanish Society of Cardiology, Ferrer International, Terumo, Sanofi, Novo Nordisk, Amgen, Bayer, Boehinger Ingelheim, and Daiichi-Sankyo. M. Anguita, I. Egocheaga, J.C. Obaya and V. Pallarés-Carratalá have no conflicts of interest to declare.

References


